In case of successful completion of clinical trials of the COVID-19 vaccine developed by Turkey’s Intranazal, its introduction is planned by the end of the year. This was announced by the Minister of Industry and Technology of Turkey Mustafa Varank, the Anadolu News Agency reports.
According to him, Nanography company is engaged in the development of the vaccine, which will be used in the form of a nasal spray.
“The project to develop a coronavirus vaccine in intranasal form is supported by the capital’s universities: Middle East Technical University, as well as the universities of Hacettepe, Gazi and Ankara.
Unlike vaccines based on mRNA or inactivated vaccine technologies, this vaccine is developed on the basis of protein.Since the vaccine is administered through the nose and follows the path that the infection enters the body, it is suggested that this technology may be more effective in fighting the virus,” said Mr.
Varank.
The department head noted the great potential of this vaccine in terms of adaptation in the case of a virus mutation.
“Preclinical trials of the first domestic intranasal vaccine have been successfully completed, and the first phase of human clinical trials will begin in the very near future.The vaccine is awaiting approval from the Turkish Medicines and Medical Equipment Agency.
If the clinical trials of the vaccine are successfully completed, we plan to introduce it by the end of the year,” noted the minister.